You are here: Industry Insights > Boan Biotech

News List

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit prnasia
September 28, 2021
Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021.
Boan Biotech to Start Phase II Clinical Trial in U.S. for Neutralizing Antibody Against SARS-CoV-2 firstwordpharma
June 17, 2021
Luye Pharma Group today announced that its subsidiary Boan Biotech has submitted the investigational new drug (IND) application for a self-developed drug LY-CovMab to the U.S. Food and Drug Administration.
Boan Biotech Grants AstraZeneca Exclusive Rights to Promote Boyounuo(R) (Bevacizumab Injection) in Specific County Markets of China prnasia
May 27, 2021
Luye Pharma Group announced that its holding subsidiary, Boan Biotech, has signed an agreement with AstraZeneca China regarding the promotion rights to the anticancer drug Boyounuo® (Bevacizumab Injection), under which the former will grant to the ...